HealthEquity Sets Date to Announce First Quarter Results
Presentation at ConferencesDRAPER, Utah, May 07, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") cust
Healthequity (HQY): A Strong Buy on Digital Wallet Expansion and Enhanced Profitability
20 Fastest Growing Fintech Companies In 2024
Team Member Feedback Earns HealthEquity Workplace Culture Recognition
DRAPER, Utah, May 02, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY), the nation's largest Health Savings Account (HSA) custodian has received a Culture Excellence Award by Top Workplaces for the fourth
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Cellectis SA (CLLS) and Idexx Laboratories (IDXX)
HealthEquity Board Re-Nominates Directors, Reduces Size
Healthequity (HQY) has issued an update.
Reasons Why You Should Retain HealthEquity (HQY) Stock for Now
J.P. Morgan's Analyst Focus List - 5 Adds and 1 Removal
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Healthequity (HQY) and Nuvation Bio (NUVB)
HealthEquity Expands Portfolio With Conduent Acquisition
JMP Starts HealthEquity at Market Outperform, Cites Revenue Growth
HealthEquity Initiated at Market Outperform by JMP Securities
HealthEquity Initiated at Market Outperform by JMP Securities
JMP Securities Initiates Coverage On HealthEquity With Market Outperform Rating, Announces Price Target of $101
JMP Securities analyst Constantine Davides initiates coverage on HealthEquity with a Market Outperform rating and announces Price Target of $101.
HealthEquity's Market Leadership and Growth Trajectory Bolster Buy Rating
Why HealthEquity (HQY) Is a Top Growth Stock for the Long-Term
Are Investors Undervaluing HealthEquity, Inc. (NASDAQ:HQY) By 49%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, HealthEquity fair value estimate is US$161 HealthEquity is estimated to be 49% undervalued based on current share price of US$82.79 The US
HealthEquity Is a Top Pick at JPMorgan on Near-term Outlook
HealthEquity Is Maintained at Overweight by JP Morgan
HealthEquity Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on HealthEquity, Raises Price Target to $108
JP Morgan analyst Anne Samuel maintains HealthEquity with a Overweight and raises the price target from $86 to $108.
HealthEquity Poised for Strong Growth: Buy Rating With a $108 Price Target
No Data